ID: ALA1269727

Max Phase: Preclinical

Molecular Formula: C14H11BrN2O2

Molecular Weight: 319.16

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc2oc(Nc3cccc(Br)c3)nc2c1

Standard InChI:  InChI=1S/C14H11BrN2O2/c1-18-11-5-6-13-12(8-11)17-14(19-13)16-10-4-2-3-9(15)7-10/h2-8H,1H3,(H,16,17)

Standard InChI Key:  ACSVVIUPZPFHSQ-UHFFFAOYSA-N

Associated Targets(non-human)

Arachidonate 5-lipoxygenase 121 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 319.16Molecular Weight (Monoisotopic): 318.0004AlogP: 4.34#Rotatable Bonds: 3
Polar Surface Area: 47.29Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 10.69CX Basic pKa: 0.17CX LogP: 4.06CX LogD: 4.05
Aromatic Rings: 3Heavy Atoms: 19QED Weighted: 0.78Np Likeness Score: -1.42

References

1. Song H, Oh SR, Lee HK, Han G, Kim JH, Chang HW, Doh KE, Rhee HK, Choo HY..  (2010)  Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors.,  18  (21): [PMID:20870413] [10.1016/j.bmc.2010.08.047]

Source